Dr. Peter Sallstig has nearly 20 years of experience in the global pharmaceutical industry. His expertise includes clinical development, medical affairs, and regulatory approval and launch, with roles spanning from product development strategy to program leadership and clinical operations. He has extensive background working with global health authorities, payers, clinical experts and key opinion leaders advancing programs through successful registration and product launches across multiple therapeutic areas. Prior to joining Santen, Dr. Sallstig served as Vice President, Head of Clinical Development at InsMed, Inc. His previous positions include serving as Head, Clinical Development of the Pharma Franchise for Novartis/Alcon. There, he successfully proposed, developed and advanced the global clinical strategy from design phase to submission and approval for retina, anti-infectives, dry eye, allergy and inflammation, and glaucoma therapeutic areas. Dr. Sallstig obtained an MBA from the Open University Business School in the United Kingdom and an MD from the Semmelweis University of Medicine in Hungary.